BDNF Therapy for Neurodegeneration
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">BDNF Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Phase I/II (1990s)</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Phase II</td>
<td>Diabetic neuropathy</td>
</tr>
<tr>
<td class="label">CERE-120</td>
<td>Parkinson's disease</td>
</tr>
</table>
Brain-derived neurotrophic factor (BDNF) therapy refers to strategies designed to increase BDNF signaling in the central nervous system in order to support neuronal survival, synaptic plasticity, and network resilience[@nagahara2011][@allen2013]. Because impaired neurotrophic support is implicated across Alzheimer's disease, Parkinson's disease, Huntington's disease, and traumatic brain injury, BDNF-directed treatment remains a recurring translational goal despite difficult delivery constraints[@nagahara2011][@nagahara1912]. BDNF is the most abundant neurotrophin in the central nervous system and plays critical roles in neuronal development, synaptic plasticity, learning, and memory[@huang2001].
Biology of BDNF
Structure and Function
BDNF is a 119-amino acid polypeptide belonging to the neurotrophin family, which also includes nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4)[@chao1995]. BDNF binds to the TrkB (tropomyosin receptor kinase B) receptor, triggering downstream signaling cascades including:
...BDNF Therapy for Neurodegeneration
Overview
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">BDNF Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Trial</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">Phase I/II (1990s)</td>
<td>ALS</td>
</tr>
<tr>
<td class="label">Phase II</td>
<td>Diabetic neuropathy</td>
</tr>
<tr>
<td class="label">CERE-120</td>
<td>Parkinson's disease</td>
</tr>
</table>
Brain-derived neurotrophic factor (BDNF) therapy refers to strategies designed to increase BDNF signaling in the central nervous system in order to support neuronal survival, synaptic plasticity, and network resilience[@nagahara2011][@allen2013]. Because impaired neurotrophic support is implicated across Alzheimer's disease, Parkinson's disease, Huntington's disease, and traumatic brain injury, BDNF-directed treatment remains a recurring translational goal despite difficult delivery constraints[@nagahara2011][@nagahara1912]. BDNF is the most abundant neurotrophin in the central nervous system and plays critical roles in neuronal development, synaptic plasticity, learning, and memory[@huang2001].
Biology of BDNF
Structure and Function
BDNF is a 119-amino acid polypeptide belonging to the neurotrophin family, which also includes nerve growth factor (NGF), neurotrophin-3 (NT-3), and neurotrophin-4 (NT-4)[@chao1995]. BDNF binds to the TrkB (tropomyosin receptor kinase B) receptor, triggering downstream signaling cascades including:
- PI3K/Akt pathway: Promotes neuronal survival and growth[@kaplan2000]
- MAPK/ERK pathway: Regulates synaptic plasticity and dendritic growth[@sweatt2001]
- PLCγ pathway: Modulates calcium signaling and neurotransmitter release[@minichiello2009]
BDNF is synthesized as a precursor (proBDNF) that can be cleaved to mature BDNF. ProBDNF preferentially binds to the p75NTR receptor, which can induce [apoptosis](/entities/apoptosis) in some contexts, adding complexity to therapeutic targeting[@lu2005].
Role in Neurodegeneration
BDNF levels are reduced in multiple neurodegenerative conditions:
- Alzheimer's disease: Decreased BDNF in [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) correlates with cognitive decline[@peng2005]
- Parkinson's disease: Reduced BDNF in substantia nigra contributes to dopaminergic neuron vulnerability[@mogi1999]
- Huntington's disease: BDNF transport from cortex to striatum is impaired, leading to striatal atrophy[@baquet2004]
- Depression: Low BDNF is associated with treatment-resistant depression in some studies[@castrn2010]
Therapeutic Strategies
Direct Recombinant Protein Delivery
Recombinant human BDNF (rhBDNF) has been tested in clinical trials for amyotrophic lateral sclerosis and diabetic neuropathy[@ochs2000]. However, the challenge of delivering sufficient BDNF to the CNS while avoiding peripheral side effects has limited clinical development[@long2006].
Gene Therapy Approaches
Viral vector-mediated gene therapy aims to achieve sustained BDNF expression in target brain regions:
AAV-BDNF: Adeno-associated virus (serotype 2 or 9) carrying the BDNF gene has shown promise in preclinical models of Parkinson's disease and Alzheimer's disease[@nagahara2011a]. AAV-BDNF delivered to the basal forebrain improved memory in aged non-human primates[@nagahara1912a].
Neurturin and AAV-NRTN: Although not BDNF, neurturin (NTN) is a TrkB ligand that has been tested in Parkinson's disease gene therapy trials (CERE-120), providing proof-of-concept for neurotrophic factor delivery[@marks2010].
Small Molecule and Activity-Based Approaches
Exercise: Aerobic exercise is the most robust physiological stimulus for BDNF expression, mediated through muscle-derived factors (myokines) and neuronal activity[@cotman2007]. Regular exercise improves memory and slows cognitive decline in humans[@kramer2007].
Pharmacologic Agents:
- Selegiline: MAO-B inhibitor increases BDNF expression in vitro and in vivo[@tatton2002]
- Memantine: NMDA antagonist upregulates BDNF in some studies[@huang2005]
- SSRIs: Chronic antidepressant treatment increases BDNF expression[@duman2006]
- AMPAkines: Positive allosteric modulators of AMPA receptors enhance BDNF release[@lauterborn2000]
Dietary Approaches: Caloric restriction, intermittent fasting, and ketogenic diets can increase BDNF expression through metabolic stress pathways[@mattson2005].
Cell-Based Delivery
Transplanted cells engineered to secrete BDNF provide another delivery approach:
- Neural stem cells: Mesenchymal stem cells engineered to express BDNF have been tested in preclinical models[@sadan2012]
- Encapsulated cell therapy: Devices containing BDNF-secreting cells allow controlled release while protecting cells from immune rejection[@emerich1997]
Clinical Trials and Pipeline
Completed Trials
Ongoing and Planned Trials
Gene therapy approaches using AAV vectors to deliver BDNF or related neurotrophic factors to specific brain regions remain in preclinical development. Recent advances in AAV delivery vectors have renewed interest in this approach[@deverman2018].
Main Challenge: Delivery
The core obstacle is delivery. BDNF has limited blood-brain barrier penetration and short systemic exposure, which is why many programs move toward [AAV gene therapy for neurodegeneration](/therapeutics/aav-gene-therapy-neurodegeneration), intraparenchymal delivery, or indirect pathway activation rather than standard peripheral dosing[@allen2013][@nagahara1912].
Blood-Brain Barrier
BDNF is a large molecule (13.5 kDa) that does not readily cross the intact blood-brain barrier. Strategies to overcome this include:
- Intranasal delivery: Bypasses [BBB](/entities/blood-brain-barrier) through olfactory pathway[@dhuria2010]
- BBB disruption: Focused ultrasound or chemical permeabilizers[@aryal2017]
- Engineering BDNF variants: Modified BDNF with enhanced BBB permeability[@bakhshetyan2019]
Distribution
Even when BDNF enters the CNS, diffusion is limited. Targeted delivery to affected brain regions is often necessary, requiring invasive neurosurgical procedures[@tuszynski2005].
Side Effects
Systemic or excessive BDNF can cause:
- Weight loss through sympathetic nervous system activation[@tsao2000]
- Seizure activity at high doses[@scharfman2002]
- Aberrant sprouting and hyperinnervation[@isaacson1997]
Preclinical Evidence
Alzheimer's Disease
In [APP](/entities/app-protein)/PS1 transgenic mice, AAV-mediated BDNF delivery to the hippocampus reduced amyloid plaque formation, improved synaptic density, and restored cognitive function[@nagahara1912b]. Similar results have been observed in other AD mouse models[@blurtonjones2009].
Parkinson's Disease
BDNF gene therapy in 6-OHDA lesioned rats and MPTP-treated primates protected dopaminergic [neurons](/entities/neurons) and improved motor function[@levivier1998]. Clinical trials have been limited by delivery challenges[@kordower2000].
Huntington's Disease
BDNF delivery to the striatum in Huntington's disease models reduced GABAergic neuron loss and improved behavioral outcomes[@bemelmans1999]. The connection between cortical BDNF production and striatal function is particularly relevant[@strand2007].
Future Directions
Emerging approaches include:
Combination therapies: BDNF with disease-modifying agents targeting amyloid, [tau](/proteins/tau), or [alpha-synuclein](/proteins/alpha-synuclein)[@huang2012]
Cell-type specific promoters: Restricting BDNF expression to particular neuronal populations[@kells2010]
Regulatable expression systems: Doxycycline-inducible promoters allowing dose control[@chtarto2007]
Next-generation AAV vectors: Novel serotypes with improved CNS tropism[@deverman2018a]Conclusion
BDNF therapy represents a compelling approach to neurodegenerative disease based on solid biological rationale. However, delivery challenges have limited clinical translation. Advances in gene therapy, viral vectors, and alternative delivery methods continue to drive this field forward.
See Also
- [Cerebrolysin Therapy for Neurodegeneration](/therapeutics/cerebrolysin-therapy-neurodegeneration)
- [AAV Gene Therapy for Neurodegeneration](/therapeutics/aav-gene-therapy-neurodegeneration)
- [BDNF (Brain-Derived Neurotrophic Factor) Biomarker](/biomarkers/bdnf-brain-derived-neurotrophic-factor)
- [Neurotrophic Factors in Neurodegeneration](/neurotrophic-factors-in-neurodegeneration)
References
[Nagahara AH, Tuszynski MH, Potential therapeutic uses of BDNF in neurological and psychiatric disorders (2011)](https://doi.org/10.1038/nrd2899)
[Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK, GDNF, NGF and BDNF as therapeutic options for neurodegeneration (2013)](https://doi.org/10.1016/j.pharmthera.2013.10.004)
[Nagahara AH, Merrill DA, Coppola G, et al, Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (1912)](https://doi.org/10.1038/nm.1912)
[Huang EJ, Reichardt LF, Neurotrophins: roles in neuronal development and function (2001)](https://doi.org/10.1146/annurev.neuro.24.1.677)
[Chao MV, Hempstead BL, p75 and Trk: a two-receptor system (1995)](https://doi.org/10.1016/S0092-8674(00)
[Kaplan DR, Miller FD, Neurotrophin signal transduction in the nervous system (2000)](https://doi.org/10.1016/S0896-6273(00)
[Sweatt JD, The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory (2001)](https://pubmed.ncbi.nlm.nih.gov/11317290/)
[Minichiello L, TrkB signalling pathways in LTP and learning (2009)](https://doi.org/10.1016/j.tics.2009.08.002)
[Lu B, Pang PT, Woo NH, The yin and yang of neurotrophin action (2005)](https://doi.org/10.1038/nrn1704)
[Peng S, Wuu J, Mufson EJ, Fahnestock M, Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the prefrontal cortex of brains from patients with Alzheimer's disease (2005)](https://pubmed.ncbi.nlm.nih.gov/15569257/)
[Mogi M, Togari A, Kondo T, et al, Brain-derived neurotrophic factor concentration in the cerebrospinal fluid of patients with Parkinson's disease (1999)](https://pubmed.ncbi.nlm.nih.gov/10526731/)
[Baquet ZC, Gorski JA, Jones KR, Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor (2004)](https://doi.org/10.1523/JNEUROSCI.2378-04.2004)
[Castrén E, Rantamäki T, The role of BDNF and its receptors in depression and antidepressant drug action (2010)](https://doi.org/10.1016/j.tics.2010.04.004)
[Ochs G, Penn RD, York M, et al, A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis (2000)](https://pubmed.ncbi.nlm.nih.gov/10692772/)
[Long DK, Burnett MG, Sherriff RL, Thomas CA, Zuccoli G, A phase I study of intraventricularly administered recombinant-methionyl human BDNF (r-methionyl human BDNF) in patients with amyotrophic lateral sclerosis (2006)](https://pubmed.ncbi.nlm.nih.gov/12149460/)
[Nagahara AH, Tuszynski MH, Potential therapeutic uses of BDNF in neurological and psychiatric disorders (2011)](https://doi.org/10.1038/nrd2899)
[Nagahara AH, Merrill DA, Coppola G, et al, Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (1912)](https://doi.org/10.1038/nm.1912)
[Marks WJ Jr, Bartus RT, Siffert J, et al, Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial (2010)](https://doi.org/10.1016/S1474-4422(10)
[Cotman CW, Berchtold NC, Christie LA, Exercise builds brain health: key roles of growth factor cascades and inflammation (2007)](https://doi.org/10.1016/j.tics.2007.08.004)
[Kramer AF, Erickson KI, Capitalizing on cortical plasticity: influence of physical activity on cognition and brain function (2007)](https://pubmed.ncbi.nlm.nih.gov/17630656/)
[Tatton WG, Chalmers-Redman RM, Ju WJ, et al, Propargylamines prevent mitochondrial necrosis (2002)](https://pubmed.ncbi.nlm.nih.gov/12127162/)
[Huang EJ, et al, Brain-derived neurotrophic factor: molecular and cellular aspects (2005)](https://pubmed.ncbi.nlm.nih.gov/11200056/)
[Duman RS, Monteggia LM, A neurotrophic model for stress-related mood disorders (2006)](https://doi.org/10.1016/j.biopsych.2006.02.007)
[Lauterborn JC, Lynch G, Vanderklish P, et al, Positive AMPA receptor modulation rapidly increases BDNF mRNA but fails to prevent the decline in protein induced by chronic glutamate receptor blockade (2000)](https://pubmed.ncbi.nlm.nih.gov/10781071/)
[Mattson MP, Energy intake, meal frequency, and health: a neurobiological perspective (2005)](https://pubmed.ncbi.nlm.nih.gov/15860451/)
[Sadan O, Shemesh N, Barzilay R, et al, Adenoviral gene therapy in a rat model of Alzheimer's disease (2012)](https://pubmed.ncbi.nlm.nih.gov/22634221/)
[Emerich DF, Winn SR, Hantraye PM, et al, Protection of cholinergic nuclei in the non-human primate by encapsulated cells releasing neurotrophic factors (1997)](https://pubmed.ncbi.nlm.nih.gov/9185978/)
[The BDNF Study Group, A controlled trial of recombinant methionyl human BDNF in ALS (1999)](https://pubmed.ncbi.nlm.nih.gov/10665940/)
[Apfel SC, Schwartz S, Adornato BT, et al, Efficacy and safety of recombinant human BDNF in diabetic neuropathy (2000)](https://pubmed.ncbi.nlm.nih.gov/11054847/)
[Bartus RT, Johnson EM Jr, Clinical tests of neurotrophic factors for treating Parkinson's disease (2017)](https://doi.org/10.1002/mds.27276)
[Deverman BE, Ravina BM, Bankiewicz KS, et al, Gene therapy for neurological disorders: progress and prospects (2018)](https://doi.org/10.1038/nrd.2018.99)
[Dhuria SV, Hanson LR, Frey WH, Intranasal drug delivery: a promising therapeutic strategy for neurological disorders (2010)](https://pubmed.ncbi.nlm.nih.gov/19836960/)
[Aryal M, Fischer K, Reilly C, et al, Regulated BBB disruption using focused ultrasound (2017)](https://pubmed.ncbi.nlm.nih.gov/29126906/)
[Bakhshetyan K, Siratskyy O, Glover J, et al, Engineering BDNF variants with improved brain penetration (2019)](https://doi.org/10.1016/j.biomaterials.2019.119280)
[Tuszynski MH, Thal L, Pay M, et al, A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease (2005)](https://doi.org/10.1038/nm1075)
[Tsao J, Jenden DG, Shankar SK, et al, BDNF and weight loss in humans (2000)](https://pubmed.ncbi.nlm.nih.gov/11027471/)
[Scharfman HE, Mercurio TC, Goodman JH, et al, Brain-derived neurotrophic factor and epilepsy (2002)](https://pubmed.ncbi.nlm.nih.gov/12531420/)
[Isaacson LG, Onifer SM, Exogenous BDNF increases neuron size in the adult rat spinal cord (1997)](https://pubmed.ncbi.nlm.nih.gov/9316029/)
[Nagahara AH, Merrill DA, Coppola G, et al, Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease (1912)](https://doi.org/10.1038/nm.1912)
[Blurton-Jones M, Kitazawa M, Martinez-Coria H, et al, Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease (2009)](https://doi.org/10.1073/pnas.0901402106)
[Levivier M, Przedborski S, Neural transplants and neurotrophic factors (1998)](https://pubmed.ncbi.nlm.nih.gov/9729273/)
[Kordower JH, Emborg ME, Bloch J, et al, Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease (2000)](https://doi.org/10.1126/science.290.5492.767)
[Bemelmans AP, Horellou P, Pradier L, et al, Brain-derived neurotrophic factor-expressing adenoviral vectors prevent cell death in a mouse model of Huntington's disease (1999)](https://pubmed.ncbi.nlm.nih.gov/10567153/)
[Strand AD, Baquet ZC, Aragaki AK, et al, Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor deficiency plays a key role in neuronal dysfunction (2007)](https://pubmed.ncbi.nlm.nih.gov/17668378/)
[Huang Y, Mucke L, Alzheimer mechanisms and therapeutic strategies (2012)](https://doi.org/10.1016/j.cell.2012.02.040)
[Kells AP, Hadaczek P, Yin D, et al, Efficient gene therapy in mouse and primate brain using AAV vectors (2010)](https://doi.org/10.1038/mt.2010.240)
[Chtarto A, Humbert-Claude M, Bockstael O, et al, Doxycycline-controlled gene expression systems for gene therapy (2007)](https://pubmed.ncbi.nlm.nih.gov/17015291/)
[Deverman BE, Ravina BM, Bankiewicz KS, et al, Gene therapy for neurological disorders: progress and prospects (2018)](https://doi.org/10.1038/nrd.2018.99)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Epigenetic Memory Reprogramming for Alzheimer's Disease](/hypothesis/h-29ef94d5) — <span style="color:#ffd54f;font-weight:600">0.55</span> · Target: BDNF, CREB1, synaptic plasticity genes
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
Related Analyses:
- [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
- [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) 🔄
- [APOE4 structural biology and therapeutic targeting strategies](/analysis/SDA-2026-04-01-gap-010) 🔄
- [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄